| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_241c3d4e236532a2e822eb39f56b1be9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e13cf25eb1bef6199475314477618b46 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5383
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-536 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5383 |
| filingDate |
2013-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d80174086435bfeb32b0e9ce85fd6c12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6943f3dbf8500fd080e308f99a2b92ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13e84c1d30ec7f7de24af04ed3b3a689
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b448d56924e39f68e09c7c35c69322b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b70365b68fa74c898f73f46982994f4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_509b725bbed96f8e4b959bd493f65863 |
| publicationDate |
2013-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2013241464-A |
| titleOfInvention |
Eye drops for treatment of conjunctivitis containing levofloxacin or a salt thereof or a solvate thereof |
| abstract |
[PROBLEMS] To search for a levofloxacin ophthalmic solution of a dose that cures an eye infection in a shorter period of time and does not increase the incidence of side effects than conventional levofloxacin ophthalmic solution to prevent the appearance of levofloxacin-resistant bacteria. . A drop of levofloxacin at a concentration of 1.5% (w / v) is instilled 3 times a day. [Effects] Bacterial conjunctivitis is cured in a shorter period of time than the conventional use or dose of 0.5% (w / v) ophthalmic solution three times a day, and the incidence of side effects is not increased. It directly inhibits the resistance of pathogenic bacteria such as Staphylococcus aureus caused by short-term use of conventional usage or doses of levofloxacin ophthalmic solution. [Selection] Figure 2 |
| priorityDate |
2010-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |